دورية أكاديمية

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.

التفاصيل البيبلوغرافية
العنوان: Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
المؤلفون: Dimopoulos, Meletios A., Moreau, Philippe, Augustson, Bradley, Castro, Nelson, Pika, Tomas, Delimpasi, Sosana, De la Rubia, Javier, Maiolino, Angelo, Reiman, Tony, Martinez‐Lopez, Joaquin, Martin, Thomas, Mikhael, Joseph, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaelle, Marion, Sylvia, Hajek, Roman
المصدر: American Journal of Hematology; Jan2023, Vol. 98 Issue 1, pE15-E19, 5p
قاعدة البيانات: Complementary Index
الوصف
تدمد:03618609
DOI:10.1002/ajh.26602